Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy.
SARS-CoV-2
anti-CD20 therapy
interferon-gamma release assay
multiple sclerosis
ocrelizumab
vaccination
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
07 Sep 2023
07 Sep 2023
Historique:
received:
26
07
2023
revised:
04
09
2023
accepted:
04
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Our objective was to analyze longitudinal cellular and humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in people with multiple sclerosis (pwMS) on B-cell depleting treatment (BCDT) compared to pwMS without immunotherapy. We further evaluated the impact of COVID-19 infection and vaccination timing. PwMS (
Identifiants
pubmed: 37766140
pii: vaccines11091464
doi: 10.3390/vaccines11091464
pmc: PMC10537223
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Roche (Germany)
ID : Fonds Nr. 105.1067, PO Nr. EPBA2688985-A46
Références
Front Neurol. 2022 Nov 10;13:1032830
pubmed: 36438945
Neurol Ther. 2023 Apr;12(2):687-700
pubmed: 36792812
Mult Scler. 2022 Jun;28(7):1041-1050
pubmed: 35575234
Neurology. 2022 Feb 1;98(5):e541-e554
pubmed: 34810244
Mult Scler Relat Disord. 2022 Dec;68:104371
pubmed: 36544318
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34907916
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):960-971
pubmed: 35835468
Ann Clin Transl Neurol. 2022 Oct;9(10):1643-1659
pubmed: 36165097
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
J Neurol Neurosurg Psychiatry. 2022 Sep;93(9):978-985
pubmed: 35193952
J Clin Invest. 2021 Sep 1;131(17):
pubmed: 34623327
J Neurol. 2022 Dec;269(12):6185-6192
pubmed: 35879563
Front Immunol. 2022 Aug 18;13:946356
pubmed: 36059537
Front Immunol. 2022 Jan 19;12:798117
pubmed: 35126362
Mult Scler Relat Disord. 2023 Mar;71:104574
pubmed: 36827874
Elife. 2022 Jul 15;11:
pubmed: 35838348
JAMA Neurol. 2022 Mar 1;79(3):307-309
pubmed: 35072702
Neurol Neuroimmunol Neuroinflamm. 2022 May 6;9(4):
pubmed: 35523569
Lancet Reg Health Eur. 2021 Oct;9:100178
pubmed: 34318288
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
Front Immunol. 2021 Dec 09;12:781843
pubmed: 34956211
Ann Neurol. 2022 Mar;91(3):342-352
pubmed: 35067959
J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):280-283
pubmed: 36564175
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 12;9(6):
pubmed: 36224045
Mult Scler Relat Disord. 2022 Apr;60:103729
pubmed: 35334278
EBioMedicine. 2021 Nov;73:103636
pubmed: 34666226
Front Immunol. 2022 Apr 01;13:868915
pubmed: 35432335
JCI Insight. 2022 Feb 22;7(4):
pubmed: 35030101
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Eur J Immunol. 2022 Dec;52(12):1961-1971
pubmed: 36250411
Front Immunol. 2022 Dec 23;13:1037214
pubmed: 36618356
Front Immunol. 2022 Aug 05;13:926318
pubmed: 35990701
Neurol Neuroimmunol Neuroinflamm. 2022 Nov 17;10(1):
pubmed: 36396447
Mult Scler Relat Disord. 2022 Jun;62:103800
pubmed: 35462168
Mult Scler Relat Disord. 2022 May;61:103776
pubmed: 35364386
J Neurol. 2023 May;270(5):2380-2391
pubmed: 36933032
Ann Neurol. 2022 Jun;91(6):796-800
pubmed: 35243687
Mult Scler Relat Disord. 2022 Apr;60:103724
pubmed: 35272145
JAMA Neurol. 2022 Apr 01;79(4):399-404
pubmed: 35212717
Mult Scler Relat Disord. 2023 Feb;70:104484
pubmed: 36608538